MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
Business Overview
The Thai private hospital industry is projected to see revenue growth of 3.1% YoY in 2026, reaching a market value of approximately 350 billion Baht. Despite pressures from Thailand’s fragile and low-growth economy, which has slowed the domestic patient segment's growth to 2.9% YoY, the business remains supported by critical structural drivers. These include the transition into a 'Super-Aged Society' since 2024 and the rising incidence of Non-Communicable Diseases (NCDs). Revenue from international patients is expected to grow by 4.3% YoY, bolstered by the recovery of long-haul tourist markets, particularly from Scandinavia (Norway, Sweden, and Denmark). These high-potential markets favor long-stay visits and wellness programs, aligning with Thailand’s push to become a 'Global Health Destination' through the 'WhyCation' trend. This trend focuses on Scientific Wellness and Preventative Diagnostics for Longevity. These high-quality patient segments will generate incremental revenue for hospitals that pivot toward Value-Based Care. Furthermore, the increase in direct flights to key destinations like Phuket and Chiang Mai will significantly enhance accessibility to medical services.
For the year 2025 and 2024, the Company’s medical service revenue amounted to Baht 2,330 million and Baht 2,032 million, respectively a 15% increase and an all-time high for the Company. Net profit for 2025 stood at 358 million Baht, representing a 26% growth from Baht 283 million in 2024. This growth was driven by an increase in revenue from both Outpatient (OPD) and Inpatient (IPD) departments, resulting in a net profit margin of 15% for the year 2025.
In 2025, medical service revenue exceeded the Company’s target of Baht 2,235 million by 4%, while the profit margin also outperformed expectations. The primary factors driving this overperformance include the Company’s enhanced capability in treating complex medical conditions and the robust growth of the international patient segment. Furthermore, the domestic patient base continued to expand despite pressures from Thailand’s fragile and low-growth economy. These factors, combined with highly effective cost and expense management, contributed to the stronger-than-expected financial results.
Regarding the operational direction for 2026, the Company has set a revenue growth target of approximately 18%. This growth is driven by several key factors: a projected increase in high-margin international patients and the expansion of specialized medical services for complex diseases. Furthermore, the Company is prepared to launch operations for two new subsidiaries in 2026: Koon Wattanapat Co., Ltd. (scheduled to open in March 2026) and Wattanapat Phuket Hospital Co., Ltd. (expected to commence operations in October 2026).
Operating Results & Financial Condition
Operating Results & Profitability
Operating results and profitability
Statement of profit and loss
Revenue from medical services
In 2025, the Company’s revenue grew by 14.6%, driven by expansion in both domestic and international patient segments. Notably, international patient revenue saw a significant surge of 35.8%, with all three subsidiaries reporting growth. This represents a consistent upward trend for three consecutive years following the COVID-19 pandemic. Key international markets include Europe and the America, with a growing contribution from the Middle East in recent periods. Meanwhile, domestic patient revenue increased by 5.0%. Regarding revenue by service type, both segments demonstrated solid growth. Outpatient (OPD) revenue rose by 15.4%, while Inpatient (IPD) revenue increased by 14.4%.
The primary drivers of revenue growth in 2025 were the significant expansion across critical service units, including the Emergency Room (ER), Operating Room (OR), Intensive Care Unit (ICU), Intermediate Care Unit (IMU), and the Cardiac Catheterization Laboratory (Cath Lab). Growth was also bolstered by specialized medical excellence in Neurosurgery and Gastroenterology. Furthermore, the Company and its subsidiaries have successfully elevated their clinical capabilities to provide advanced care for complex diseases and elderly-related conditions. This enhancement in specialized medical services has significantly boosted patient confidence, leading to increased service utilization and serving as a vital factor in strengthening the Group’s overall competitive advantage.
Cost of medical treatment
In 2025, the company's cost of medical treatment increased by 12.0%. Notably, this cost grew at a lower rate than revenue, resulting in a 20% increase in gross profit and an improved gross profit margin. The primary cost drivers included doctor fee, depreciation, and personnel expenses, including training and development costs to support the upcoming expansion of two new subsidiaries. Conversely, utility expenses decreased following the implementation of a solar energy system at the parent company in late September 2025. This initiative reduced monthly electricity costs by more than 10%, with further savings expected in the following year as the system operates for a full annual cycle. However, the Company continued to incur preparatory personnel costs to ensure operational readiness for the two new subsidiaries scheduled to commence operations in 2026.
Selling and administrative expenses
In 2025, Selling and Administrative (SG&A) expenses increased by 22.0%. This rise was primarily driven by higher sales commissions and promotional costs aligned with the significant growth in international patient revenue. Additionally, the Company intensified its proactive marketing and public relations efforts to launch new specialized medical centers and hospital services. Furthermore, the Company invested in comprehensive personnel development and specialized training programs, such as Maritime Emergency Medical Operations, Advanced Trauma Life Support, and Specialized Emergency Nursing, among others. SG&A expenses also included preparatory costs for human resources to ensure operational readiness for the two new subsidiaries scheduled to commence operations in 2026.
Financial costs
In 2025, the company’s financial costs from institutional borrowings decreased by 16.4%. This reduction was primarily driven by continuous loan repayments across all three subsidiaries (WPH, WPA, and WPS) and a downward trend in interest rates since the beginning of the year. Furthermore, this improvement reflects the Company’s strategy to optimize its capital structure while maintaining strict and consistent financial discipline. Regarding the interest expenses incurred from loans for the construction of Wattanapat Hospital Phuket (scheduled to open in October 2026), such costs are capitalized as part of the cost of land and buildings during the construction period, in accordance with accounting standards.
Income tax expense
In 2025, the Company’s income tax expense increased significantly, corresponding to the substantial growth in net profit compared to the previous year.
Net profit
In 4Q2025, the Company’s net profit surged by 51.6% with a Net Profit Margin of 16.4%. For the year 2025, net profit increased by 26.4%, achieving a Net Profit Margin of 15.3%. This growth was driven by robust revenue expansion and enhanced efficiency in managing selling and administrative expenses. Key strategies included a centralized management structure and a flexible medical staff rotation policy across the Company’s network, optimized to meet fluctuating workloads at each hospital. Furthermore, excluding the preparatory expenses for the two new subsidiaries, the adjusted net profit for 4Q2025 and the year 2025 would be Baht112 million and Baht 374 million, representing significant increases of 61.6% and 32.1%, respectively.
Statement of financial position
Total assets
As of December 31, 2025, the Company’s total assets amounted to Baht 3,582 million, representing a significant increase of 28.7% compared to the previous year. This growth was primarily driven by strategic investments in land acquisition and the ongoing construction of Wattanapat Hospital Phuket and Koon Wattanapat Hospital. Furthermore, the increase reflects continuous improvements to inpatient (IPD) wards, the launch of new specialized medical centers, and the procurement of advanced high-value medical equipment for both the parent company and its subsidiaries.
Total liabilities
As of December 31, 2025, the Company’s total liabilities amounted to Baht 1,536 million, representing an increase of 31.8%. This growth was primarily attributed to the drawdown of long-term loans by the subsidiary to fund land acquisition and the ongoing construction of Wattanapat Hospital Phuket .
Shareholders' equity
As of December 31, 2025, the Company’s shareholders’ equity amounted to Baht 2,047 million, an increase of 26.4%. This growth was primarily attributed to the net profit generated during the year 2025 and the capital injection for the increased registered capital in two subsidiaries scheduled to commence operations in 2026.
Liquidity & Capital Adequacy
Cash Flow
Net cash flows from operating activities in 2025 Increased from 2024 by Baht 58.74 million. This improvement was primarily driven by robust revenue growth and stronger operating performance, combined with enhanced efficiency in debt collection and accounts receivable management.
Net cash flows used in investing activities in 2025 The majority of the cash outflows were allocated towards investments in revenue-generating fixed assets. These include procurement of advanced medical equipment and the expansion of specialized medical centers, such as Trauma Center and Cardiac Catheterization Laboratory (Cath Lab). Additionally, significant investments were made in land acquisition and the ongoing construction of Wattanapat Phuket Hospital and Koon Wattanapat Hospital (its subsidiaries), aimed at driving long-term revenue growth.
Net cash flows used in financing activities in 2025 Cash inflows were primarily derived from new borrowings to fund the land acquisition and construction of Wattanapat Hospital Phuket (a subsidiary). Simultaneously, the Company continued to service its existing debt by repaying long-term loans from financial institutions for operational hospitals according to their respective maturity schedules.
Liquidity Ratio
As of December 31, 2025, and December 31, 2024, the Company’s Current Ratio stood at 0.97 times and 1.07 times, respectively. During the same periods, the Quick Ratio was recorded at 0.81 times and 0.83 times. An analysis of these liquidity ratios demonstrates that the Company has effectively managed its operational working capital, maintaining a balance that supports ongoing business activities and financial obligations.
Cash Cycle
For the year 2025 and 2024, the Company’s average cash conversion cycle stood at approximately 25 days and 22 days, respectively. This indicates that the Company requires cash reserves to support its business operations for an average period of 25 days. Traditionally, the Company has primarily utilized internal cash flows to manage its liquidity and ensure smooth operational continuity.
Asset Management Capability
Average collection period
For the year 2025 and 2024, the Company’s average collection period stood at approximately 38 days and 34 days, respectively. The 4-day increase in the collection period was primarily attributed to the growth in revenue and patient volume from both domestic and international insurance segments. Most of these receivables remain within their respective credit terms. Furthermore, the Company has continuously enhanced its debt collection efficiency. Nevertheless, the Company has prudently recognized an allowance for expected credit losses in the financial statements in accordance with accounting standards.
Return on assets (ROA)
For the year 2025 and 2024, the Company’s Return on Assets (ROA) stood at 11.25% and 10.58%, respectively. This year-on-year improvement reflects the Company’s enhanced capability in utilizing its existing assets to generate higher revenue and net profit. Furthermore, it demonstrates increased efficiency in overall asset management and resource optimization across the organization.
Return on equity (ROE)
For the year 2025 and 2024, the Company’s Return on Equity (ROE) stood at 19.54% and 20.85%, respectively, remaining relatively consistent with the previous year. Despite a slight variation, the Company achieved significant operational growth in both revenue and net profit. This strong performance has maintained the ROE at a high level compared to industry peers, reflecting the Company's ability to generate attractive returns for its shareholders.
Debt Obligations & Off-Balance-Sheet Management
Debt Covenants and Off-Balance Sheet Management
Commitments
As of December 31, 2025, the Company and its subsidiaries had total commitments amounting to Baht 1,605.4 million.
- Capital expenditure commitments amounted to Baht 625.38 million. These commitments primarily involve land acquisitions, building construction projects, the procurement of medical tools and equipment, and the installation of information technology (IT) systems.
- Operating lease commitments amounted to Baht 5.2 million, primarily relating to the lease of residential units and operational equipment.
- Service agreement commitments amounted to Baht 11.05 million, primarily relating to security services, medical equipment maintenance, and other support services.
- Guarantees amounted to Baht 1,988.56 million, primarily arising from corporate guarantees provided for credit facilities of subsidiaries and the issuance of letters of guarantee by financial institutions.
Financial Structure Analysis
Key financial ratios of the Company. The information is shown below.
- Debt-to-equity ratio as of December 31, 2025 and 2024 was 0.75 times and 0.72 times, respectively.
- Interest coverage ratio as of December 31, 2025 and 2024 was 15.84 times and 11.75 times, respectively.
Material & Related-Party Transactions
The Company has established approval procedures for Related Party Transactions (RPT) in strict compliance with the Securities and Exchange Act, as well as the rules, regulations, notifications, and orders issued by the Securities and Exchange Commission (SEC) and the Stock Exchange of Thailand (SET). Directors or any individuals who may have a potential conflict of interest, or any vested interest in a particular transaction, are prohibited from voting on the approval of such matters. In cases where the law requires board approval for an RPT, the Company ensures that the Audit Committee attends the meeting to review and provide opinions on the necessity and reasonableness of the transaction, guided by the following principles:
• Transactions with arms-length trading terms: The Board of Directors has approved in principle that management may engage in related party transactions with arms-length trading terms if such transactions have commercial agreements similar to those that would be entered into with other parties in the same circumstances, with bargaining power free from the influence of their status as directors, executives, or connected persons (as the case may be). The company will prepare a report summarizing such transactions for reporting at the Audit Committee and Board of Directors meetings every quarter.
• Ordinary course of business transactions and transactions in support of ordinary course of business which are not on an arm's length basis, and other related party transactions, such as building rental and financial assistance transactions, such as loans, guarantees, etc. The company has a policy to propose to the Board of Directors meeting for approval, with the Audit Committee attending the meeting and providing opinions on the reasonableness and necessity of such transactions before entering into such transactions. The company must comply with the Securities and Exchange Act and the rules, announcements, orders, or regulations of the Stock Exchange of Thailand, including compliance with the regulations on disclosure of connected transactions and the acquisition or disposal of major assets of the company or its subsidiaries (if any), and compliance with the accounting standards on disclosure of information about related parties or related party transactions as prescribed by the Federation of Accounting Professions under the Royal Patronage. The company will disclose related party transactions in the notes to the company's financial statements, including the annual information / annual registration statement (Form 56-1). In addition, in the event that the Audit Committee is required to provide an opinion on the appropriateness of such transactions and the Audit Committee does not have the expertise to consider the related party transactions that occur, the company will arrange for a qualified person, such as an independent auditor or property appraiser, to provide an opinion on the related party transactions. The opinion of the Audit Committee or the qualified person will be used to inform the decision of the Board of Directors or shareholders, as the case may be, to ensure that entering into such transactions will not result in the manipulation or transfer of benefits between the company or persons who may have a conflict of interest with the company, but rather will be transactions that the company has considered in the best interests of all shareholders.
Related party transactions that may occur in the future must be reviewed by the Audit Committee and the Board of Directors, with the Audit Committee attending the meeting to consider and provide opinions on the necessity and reasonableness of such transactions. The review will also include an examination of the pricing and terms of the transactions to ensure they are comparable to those offered to unrelated third parties. Directors must comply with all established regulations and will be restricted from voting to approve any transactions in which they or any potentially conflicted individuals engage with the company. Future related party transactions will continue to be those arising from the company's normal course of business, such as employee dormitory rentals, food service and kitchen space rental agreements, medical services, and the purchase of denture materials. However, the company will conduct these transactions with transparency and in accordance with the company's related party transaction policy, strictly adhering to the regulations of the SEC, the Stock Exchange of Thailand, and other relevant agencies.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
The company assesses factors or events that may significantly impact its financial position or operations. These factors are evaluated and used to define operational procedures, key strategies, and to design continuous monitoring systems to enable the company to manage these risks effectively, such as appointing a primary responsible committee and assigning primary responsibility directly to various departments within the company.
1. Economic Factors
- Interest Rates: Higher interest rates may increase borrowing costs, affecting investment in various hospital projects.
- Inflation: Rising prices of goods and services can increase operational costs, such as medical expenses and medical supply costs.
- Economic Climate: If the overall economy is in recession, service recipients may reduce their use of medical services or decrease health insurance purchases, which affects hospital revenue.
2. Financial Factors
- Liquidity: Maintaining sufficient liquidity is crucial for timely payment of debts and expenses.
- Debt Management: Increasing debt or expanding credit lines may affect financial costs and increase the risk of default.
- Payment Collection: Managing the process of collecting payments from patients or insurance companies can affect the hospital's cash flow.
3. Legal and Regulatory Factors
- Health Care Laws: The enactment of new laws, such as changes to the health insurance system or the determination of medical treatment costs, may impact revenue and expenses.
- Financial Reporting Requirements: Changes in financial reporting standards, such as the adoption of IFRS or GAAP for accounting, can affect financial statement reporting.
4. Operational Factors
- Quality of Care: The quality of medical services and treatment affects the hospital's reputation and the number of service users.
- Medical Resources Management: The management of medical instruments, medical supplies, and personnel salaries affects operational costs.
- Patient Flow Management: Managing patient access to services, satisfaction, and service experience, including waiting times and bed management, will impact service efficiency.
5. Health Insurance Factors
- Health Insurance Reforms: Changes in health insurance policies, such as alterations in payment from insurance companies or the cancellation of certain types of coverage, may affect revenue from insured patients.
- Negotiations with Insurance Companies: Negotiating service fees with health insurance companies or price negotiations with insurance providers.
6. Competitive Factors
- Hospital Competition: The emergence of new hospitals or the expansion of competitor services in the market may affect market share and patient numbers. - Specialized Services: Launching new services or expanding high-demand services, such as surgery or specialized care, can help increase revenue.
7. Technological Factors
- Medical Technology Innovations: Investment in modern medical technology can enhance treatment efficiency and attract patients.
- Healthcare IT Systems Development: The implementation of medical information systems, such as Electronic Health Records (EHR) systems, can assist in patient data management and cost reduction, or the development of various service innovations by utilizing online media to enhance operational efficiency and increase patient satisfaction.
8. Unexpected Events
- Pandemics: Events such as disease outbreaks may lead to a large influx of patients seeking services, but they can also increase costs and create stress on the service system.
- Natural Disasters: May cause damage to hospital infrastructure and services.
- International Wars: Impacts from wars, such as tourist numbers, surging energy and commodity prices, and inflation due to the war in the Middle East.
9. Human Resources Factors
- Workforce Management: Having a sufficient number of highly skilled personnel across departments enhances service efficiency and helps reduce operational costs.
- Employee Satisfaction: Maintaining employee satisfaction and reducing turnover rates can lower training and replacement costs.
Projects or R&D Affecting Future Results
In 2024-2025, the company has invested in the following key projects:
1. Project to expand inpatient bed capacity at Wattanapat Hospital Ao Nang from 59 beds to 90 beds, with services commencing in July 2024.
2. Project to expand the capacity for vascular disease patient care at Wattanapat Hospital Ao Nang by opening a "Cardiac Catheterization Laboratory" (Cath Lab) and a Coronary Care Unit (CCU), which can be a cardiac care unit or critical care unit. This unit is specifically used for treating patients with heart and vascular conditions. All patients within the CCU have severe heart and vascular-related conditions in a critical stage. Services commenced in February 2024.
3. Project to expand the customer base for social security cardholders, supporting both outpatient and inpatient services, operational from January 2025 to present.
4. Project to expand the capacity for vascular disease patient care at Wattanapat Hospital Samui by opening a "Cardiac Catheterization Laboratory" (Cath Lab) and a Coronary Care Unit (CCU), which can be a cardiac care unit or critical care unit. This unit is specifically used for treating patients with heart and vascular conditions. All patients within the CCU have severe heart and vascular-related conditions in a critical stage. Services commenced in August 2025.
5. Project to open Koon Wattanapat Hospital (subsidiary), with services commencing in March 2026.
6. Project to open Wattanapat Hospital Phuket (subsidiary), expected to commence services in October 2026.
7. The Company expanded the capacity of the Intermediate Care Ward from 6 beds to 10 beds in 2025.

